{"id":"NCT00729924","sponsor":"Vanderbilt University","briefTitle":"Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid","officialTitle":"Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2008-08","primaryCompletion":"2011-02","completion":"2011-08","firstPosted":"2008-08-08","resultsPosted":"2015-03-03","lastUpdate":"2015-03-03"},"enrollment":40,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"BASIC_SCIENCE"},"conditions":["HIV Infections"],"interventions":[{"type":"DRUG","name":"Raltegravir","otherNames":["MK-0518"]}],"arms":[{"label":"Open label oral raltegravir","type":"EXPERIMENTAL"}],"summary":"This study is being done to find out how much of the drug raltegravir (RGV) gets into cerebrospinal fluid (CSF), compared to how much get into the blood and to find out if normal changes in a certain gene in your body affects how much RGV gets into the CSF.","primaryOutcome":{"measure":"Penetration of Raltegravir (RGV) Into Cerebrospinal Fluid (CSF) Based on Plasma Area-under-the-curve.","timeFrame":"Day 7","effectByArm":[{"arm":"Raltegravir: 400mg Orally Every 12 Hours for 7 Days (ABCB1 C/C","deltaMin":0.0066,"sd":null},{"arm":"Raltegravir: 400mg Orally Every 12 Hours for 7 Days (ABCB1 T/T","deltaMin":0.007,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.43"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["24349334"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":40},"commonTop":["post-lumbar puncture headache"]}}